Fenwick & West and Paul Hastings advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company...
ACELYRIN’s Merger with Alumis
Maze Therapeutics’ $140 Million Upsized Initial Public Offering
Fenwick & West represented Maze Therapeutics in the offering, and Davis Polk & Wardwell represented the underwriters. Maze Therapeutics, Inc. (Nasdaq: MAZE) announced its upsized initial...
Eli Lilly’s $3.2 Billion Acquisition of Morphic Holdings
Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
Johnson & Johnson’s $13.1 Billion Acquisition of Shockwave Medical
Freshfields Bruckhaus Deringer is representing Johnson & Johnson in the transaction, and Fenwick & West is representing Shockwave Medical. Johnson & Johnson (NYSE: JNJ) and Shockwave Medical,...
Gritstone bio’s $32.5 Million Common Stock Offering
Fenwick & West and Goodwin Procter represented Gritstone bio, Inc. in the offering, and Cooley represented the underwriters. Gritstone bio, Inc. (Nasdaq: GRTS) announced the pricing of...
Coinbase Global’s $1.1 Billion Convertible Notes Offering
Fenwick & West represented Coinbase Global, Inc. in the offering. Coinbase Global, Inc. (Nasdaq: COIN), a leading provider of end-to-end financial infrastructure and technology for the...
AppLovin’ Common Stock Secondary Offering and Share Repurchase
Wilson Sonsini Goodrich & Rosati advised AppLovin Corporation on the deal, and Fenwick & West advised the underwriters. AppLovin Corporation (NASDAQ: APP) (“AppLovin” or the “Company”),...
Shockwave Medical’s $750 Million Convertible Senior Notes Offering
Fenwick & West represented Shockwave Medical, Inc. in the transaction. Shockwave Medical, Inc. (Nasdaq: SWAV) announced its $750 million offering of 1.00% convertible senior notes due 2028...
Foresite Capital Management’s Acquisition of Pardes Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison LLP is advising MediPacific, Inc., while Fenwick & West LLP is advising Pardes Biosciences, Inc. in the transaction. MediPacific, Inc.,...
Coinbase’s Repurchase of Convertible Senior Notes
Fenwick represented Coinbase Global, Inc. on the deal. Coinbase Global, Inc. (Nasdaq: COIN), a leading provider of end-to-end financial infrastructure and technology for the cryptoeconomy, announced...
Morphic Therapeutic’s $276 Million Public Offering
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
Shockwave Medical’s Pending Acquisition of Neovasc
Fenwick advised Shockwave Medical, Inc. on the deal. Shockwave Medical, Inc. (NASDAQ: SWAV), a medical device company focused on the development of Intravascular Lithotripsy (IVL) to...